Capecitabine and Interferon-Alpha in Metastatic Renal Cell Carcinoma Patients With Failure on Interleukin-2 Based Regimens
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The aim of this study is to determine preliminary efficacy of capecitabine and
interferon-alpha in second-line after interleukin-2 based regimens in patients with MRCC